Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 1/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | BTK | Q06187 | 5/20 | 0.36 |
| ▸ | KDM4D | Q6B0I6 | 4/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7093642 | 1.00 | PIM1 (0.40) | PIM1PIM3PIM2CTSKBTK | |
| SCHEMBL6674052 | 0.85 | PIM1 (0.40) | PIM1PIM3PIM2CTSKBTK | |
| SCHEMBL6674047 | 0.85 | PIM1 (0.40) | PIM1PIM3PIM2CTSKBTK | |
| Hydrochloric Acid SCHEMBL7099684 | 0.78 | PIM1 (0.45) | PIM1PIM3 | |
| SCHEMBL4515418 | 0.78 | LMNA (0.38) | PIM1PIM3PIM2CTSKBTK | |
| SCHEMBL4515415 | 0.78 | LMNA (0.38) | PIM1PIM3PIM2CTSKBTK | |
| SCHEMBL7092547 | 0.77 | EEF2K (0.42) | PIM1PIM3PIM2BTKPARP1 | |
| SCHEMBL6649040 | 0.77 | EEF2K (0.42) | PIM1PIM3PIM2BTKPARP1 | |
| SCHEMBL11010270 | 0.74 | LMNA (0.66) | — | |
| SCHEMBL19200959 | 0.72 | KCNH2 (0.43) | PIM1PIM3PIM2CTSKKDM4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | WARNER-LAMBERT COMPANY | 2003-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114666-A1 | Having quinazolindione core structure; non-antibiotic resistance | ABCC1, RPS6KA1, SIGMAR1 | PIM1 1570/4885PIM3 1524/4885PIM2 2033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.